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Osteoclasts control reactivation of dormant
myeloma cells by remodelling the endosteal niche
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Multiple myeloma is largely incurable, despite development of therapies that target myeloma
cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells,
localized in specialized niches, which resist therapy and repopulate the tumour. However, little
is known about the niche, and how it exerts cell-extrinsic control over myeloma cell dormancy
and reactivation. In this study, we track individual myeloma cells by intravital imaging as they
colonize the endosteal niche, enter a dormant state and subsequently become activated to
form colonies. We demonstrate that dormancy is a reversible state that is switched ‘on’
by engagement with bone-lining cells or osteoblasts, and switched ‘off’ by osteoclasts
remodelling the endosteal niche. Dormant myeloma cells are resistant to chemotherapy that
targets dividing cells. The demonstration that the endosteal niche is pivotal in controlling
myeloma cell dormancy highlights the potential for targeting cell-extrinsic mechanisms to
overcome cell-intrinsic drug resistance and prevent disease relapse.
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C
ancer cell dormancy is a poorly understood and often
neglected stage in the evolution of many cancers, where
extrinsic signals from the tumour microenvironment
suppress active growth and proliferation, until more favourable
conditions arise1,2. This is a major clinical problem, as dormant
cancer cells may disseminate at an early stage in the disease3,
become resistant to conventional therapies that target dividing
cells1 and persist as minimal residual disease (MRD), which can
be reactivated to promote disease relapse long after treatment
cessation4. In the skeleton, dormant cells may co-exist in
equilibrium with the bone microenvironment for years before
reactivation and clinical relapse. In this regard, multiple
myeloma, a primary haematological malignancy arising in bone,
exempliﬁes the major therapeutic challenges posed by cancer cell
dormancy. While novel therapies that selectively target cell
‘intrinsic’ cancer properties have improved survival5, patients
continue to relapse and myeloma remains largely incurable.
Hence, understanding the ‘extrinsic’ environmental factors
that regulate myeloma cell dormancy is required to deliver
complementary treatment strategies to overcome drug resistance
and achieve complete remission and cure.
Recently, whole-genome sequencing has identiﬁed key driver
mutations and complex mutation patterns during the natural
history of myeloma within individual patients6. These
longitudinal analyses have revealed marked intra-clonal
heterogeneity and shifting clonal dominance during disease
progression and in response to drug treatments7–9. The ‘waxing
and waning’ of different myeloma clones (clonal tides) suggests
that cancer cell growth and proliferation are not ﬁxed genetic
programmes8,9 that follow a linear model, but rather a branching
and parallel, ‘Darwinian’, model of clonal evolution that is subject
to external selective pressures6,10. These data suggest that
myeloma cell clones are able to reversibly switch ‘on’ or ‘off’
depending on the presence of favourable or unfavourable
environmental signals. A critical component of this tumour
microenvironment is the bone niche where myeloma cells initially
colonize and are believed to reside11. However, the nature of this
niche and mechanisms that control myeloma cell occupancy are
poorly deﬁned.
Haematopoietic stem cells (HSCs) have long been known to
occupy unique niches within the bone marrow microenvironment
and this controls HSC dormancy, self-renewal and mobilization.
These specialized microenvironments contain cells of the
osteogenic lineage, perivascular cells and/or endothelial cells,
and remodelling of these niches by osteoclasts regulates niche
occupancy12–18. More recently, leukaemic cells and other cancer
cells, including prostate cancer cells, have been shown to engraft
in the HSC niche19–21. However, despite the importance of the
niche in controlling tumour cell engraftment, the dynamic
interactions between colonizing cancer cells and components of
these specialized niches, and the impact of these interactions on
the long-term fate of these cells, is poorly understood.
Studying the dynamic interactions between dormant myeloma
cells and the bone niche is particularly challenging, because it
requires high-resolution deep-tissue imaging through intact bone
in a live animal. Nevertheless, intravital microscopy of the bone
marrow space beneath the bregma in the calvarium22 has been
successfully used to study haematopoiesis23 and the HSC
niche24–27, and has recently been applied to study the
colonization of bone by leukaemic and myeloma cells20,28.
However, to date, non-destructive microscopic imaging over
periods of weeks to months is yet to be performed to
longitudinally track the fate of the same individual myeloma cells
as they become activated and escape dormancy. This would be a
signiﬁcant advance on longitudinal imaging by bioluminescence,
which lacks the image resolution and potential for simultaneous
visualization of the cells and structures that make up the bone
niche. Furthermore, it would have distinct advantages over cross-
sectional intravital microscopy, which may not capture the
heterogeneity within and between different animals. Nevertheless,
to image dormant myeloma cells in vivo, a robust method is
required to discriminate resting from actively dividing cancer cells.
Intravital dyes such as carboxyﬂuorescein succinimidyl ester, which
label intracellular proteins, have relatively short half-lives and are
unsuitable for the study of long-term cancer cell dormancy.
Fluorescent stem cell markers have been used to track HSCs and
study the epithelial stem cell niche, but these reporters may lack
speciﬁcity when used in isolation29–32.
To address this, here we have developed a method for dynamic
longitudinal imaging of dormant myeloma cells within intact long
bones of mice using intravital two-photon microscopy. Myeloma
cells are double-labelled with both ﬁxed genetic reporters and
lipophilic membrane dyes, which are retained by non-dividing
myeloma cells. Intravital microscopy is used to resolve single
tumour cells as they arrive in bone and engage in the bone niche,
to track the transition from dormancy to active growth, and to
follow the serial growth of tumour colonies by repeated imaging
of the same mouse at weekly intervals. These studies show that
myeloma cells can be held in a dormant state by osteoblast-like
cells in the endosteal niche, and this state confers dormant cells
with drug resistance. Furthermore, direct activation of osteoclasts
can remodel the endosteal surface to release dormant myeloma
cells from the niche and stochastically facilitate their reactivation
to repopulate the tumour. Thus, myeloma cell dormancy is a
reversible state controlled by the extrinsic bone microenviron-
ment, which can be manipulated to change the course of the
disease.
Results
Colonizing myeloma cells engage in the endosteal niche.
C57BL/KaLwRijHsd mice were injected with syngeneic 5TGM1-
enhanced green ﬂuorescent protein (eGFP) murine myeloma cells
and GFPþ cells arriving in the intact tibia were visualized
in real time by intravital two-photon microscopy (Fig. 1a–c;
Supplementary Movie 1). Rare colonizing myeloma cells were
observed as they migrated from the marrow space towards
endocortical bone surfaces, where they arrested (Fig. 1a–c). His-
tological analysis conﬁrmed the presence of individual CD138þ
cells adjacent to endosteal bone surfaces 1 and 3 days after
tumour cell inoculation (Fig. 1d). The majority of myeloma cells
continued to circulate through the bone marrow, where they were
only brieﬂy captured in the imaging volume as they ﬂowed
through in blood vessels (Fig. 1a–c; Supplementary Movie 2).
These circulating cells were seen throughout the duration of the
imaging period (460min), although the absolute numbers were
likely underestimated, as images were captured at 30-s intervals
(Fig. 1c). Nevertheless, real-time intravital imaging demonstrated
that individual cancer cells directly seed the endosteal bone niche
in the tibia.
Visualization of subpopulations of myeloma cells in vivo. To
investigate the heterogeneity in cell growth and proliferation within
populations of myeloma cells, we labelled 5TGM1-eGFP cells
with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine (DiD)
(Fig. 2a). In vitro cultures of double-labelled cells showed a serial
dilution of the dye mean ﬂuorescence intensity as GFPþDiDhi cells
divided and shared the label among daughter cells, which
progressively became GFPþDiDlo and ﬁnally GFPþDiDneg
(Fig. 2b,c). Next, mice were injected with double-labelled (GFPþ
DiDhi) cells, and the tibia was analysed by two-photon microscopy
and ﬂuorescence-activated cell sorting (FACS) analysis. Initially,
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Figure 1 | Intravital two-photon microscopy of cancer cells colonizing bone. (a) Still-frames capturing the arrival of a circulating tumour cell (top panels)
and colonizing tumour cell (bottom panels) in real time. Blue, bone; red, vasculature; green, 5TGM1-GFP myeloma cells. Scale bars, 50 mm. It corresponds
to Supplementary Movies 1 and 2. (b) Still-frames of the same cells in a showing egress of circulating cell from bone after 2min and retention of a
colonizing cell 41 h in the bone. Blue, bone; red, vasculature; green, 5TGM1-GFP myeloma cells. Scale bars, 20mm. (c) Proportion of cells that circulated
through or colonized the bone marrow in each experiment and total of all experiments. (d) CD138-stained sections from naive, or cell-injected mice at 1 and
3 days post injection. Single CD138þ cells (brown, black arrows), haematoxylin counterstain. Scale bars, 20mm. Data represent at least three experiments.
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Figure 2 | Labelling and tracking dormant cancer cells in vitro. (a) Schematic of DiD labelling to identify non-dividing cells. (b) FACS analysis of the DiD
level over 21 days of in vitro culture showing percentage of DiDhi and DiDneg cells (left, middle panel) and mean ﬂuorescence intensity (MFI) of the DiD
level (mean±s.e.m., one-way ANOVA). (c) Fluorescent microscopy (top panels) and FACS analysis (bottom panels) of cultured DiD-labelled cells.
Numbers indicate percentages of GFPþ cells in the gates. Scale bar, 150 mm.
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only GFPþDiDhi cells were present (Fig. 3a,b); however, as cells
engrafted and divided, the expansion of GFPþ cells was associated
with a dilution of the DiD label (Fig. 3a,b). At later time points
when myeloma burden was high, GFPþDiDhi cells, which had
retained the label, and therefore had not divided, were still
detectable (Fig. 3a,b). Interestingly, the proportion of GFPþDiDhi
cells appeared higher at day 7 and subsequent days, when com-
pared with earlier time points (Fig. 3b), suggesting that labelled cells
can recirculate for several days before eventually colonizing the
bone marrow. Two-photon imaging of the entire explanted tibia
detected non-divided GFPþDiDþ cells at all time points,
even among developing GFPþDiDneg tumours (Fig. 3c,d;
Supplementary Fig. 1; Supplementary Movie 3). Furthermore, the
numbers of GFPþDiDþ cells did not change with time, con-
ﬁrming the long-term persistence of these cells (Fig. 3d). DiD
labelling was also seen in GFPneg endogenous cells (Fig. 3e,f), which
likely reﬂects membrane transfer33, and shows the importance of
using a double-labelling approach with a ﬁxed genetic reporter,
such as GFP, to unequivocally identify engrafted tumour cells. Flow
cytometric analysis demonstrated that 470% of the GFPDiDþ
cells were Gr-1þ and/or CD11bþ myeloid cells. The GFPþDiDhi
population contained only 3.26% Gr-1þ and 3.26% CD11bþ
expressing cells (Fig. 3g–i). Thus, the GFPþDiDhi population was
highly enriched for GFPþDiDhi cells and contained o7%
contaminating Gr-1þ and/or CD11bþ cells. Furthermore, 89%
of dormant GFPþDiDhi and 96% of the GFPþDiDneg cells were
CD138þ , with no difference in intensity between the two
populations. Less than 2% of the GFPnegDiDþ population were
CD138þ and fewer than 6% were B220þ (Fig. 3g,i). B220 was not
expressed on GFPþDiDhi or GFPþDiDneg cells (Fig. 3g,i).
Consistent with this, sorted GFPþDiDhi cells expressed genes
typical of plasma cells, but not naive B cells or myeloid cells
(Fig. 3j).
A subpopulation of myeloma cells is dormant in vivo. The long-
term retention of DiD in a population of cells suggested that these
cells were dormant, whereas those that had lost DiD had
undergone membrane dye dilution due to cell proliferation. Sig-
niﬁcantly more GFPþDiDhi cells than GFPþDiDneg cells were
detected in the G0 phase of the cell cycle, as determined by Ki67
and 4,6-diamidino-2-phenylindole (DAPI) staining (Po0.001—
paired t-test; Fig. 4a,b), while signiﬁcantly less GFPþDiDhi cells
were in G1, S and G2/M phases (Po0.001, Po0.001 and Po0.05
paired t-test, respectively, Fig. 4a,b). FACS sorting and tran-
scriptional proﬁling of GFPþDiDhi and GFPþDiDneg cells from
disease-bearing mice revealed two distinct transcriptional proﬁles
with 6,262 differentially expressed genes between the two acti-
vation states (Fig. 4c–e). Genes involved in cell cycle and cell
replication were downregulated in the GFPþDiDhi population
when compared with the GFPþDiDneg population (Fig. 4f;
Supplementary Table 1). Furthermore, gene set enrichment
analysis (GSEA)34 identiﬁed gene sets inversely related to cell
cycle, and quiescent versus proliferating HSC signatures (Fig. 4g).
Thus, FACS analysis and molecular proﬁling identiﬁed
GFPþDiDhi cells as a dormant population that has undergone
limited numbers of cell divisions as a result of the downregulation
of genes that control cell cycle.
Importantly, gene expression analysis revealed that the
dormant GFPþDiDhi population had a distinct proﬁle of
differentially expressed genes when compared with activated
GFPþDiDneg cells (Fig. 4d). The 100 most signiﬁcantly
upregulated genes and 100 most signiﬁcantly downregulated
genes in GFPþDiDhi cells are shown in Supplementary Table 2.
GFPþDiDhi cells were found to highly express genes related to
immune responses, including those encoding interferon-induced
molecules and regulatory factors, which have been implicated
in controlling breast cancer bone metastasis35. Notably,
GFPþDiDhi cells also expressed higher levels of the cell
adhesion molecule Vcam1, which has also been implicated in
breast cancer metastasis36, and Axl, a member of the TAM family
of receptor tyrosine kinases, implicated in prostate cancer cell
dormancy37.
The endosteal niche reversibly controls myeloma cell growth.
We next determined the micro-anatomical location of GFPþ
DiDhi and GFPþDiDneg cells by two-photon microscopy. These
studies revealed that dormant GFPþDiDhi cells were pre-
ferentially located in direct contact with endosteal bone surfaces
(deﬁned by the second-harmonic signal from bone collagen), and
this position did not change over time (Fig. 5a–c; Supplementary
Movie 3). In contrast, activated GFPþDiDneg cells were pre-
ferentially found at locations distant from the bone surface
(Fig. 5b,c). To conﬁrm engagement of the endosteal bone niche
by dormant myeloma cells, we inoculated DiD-labelled 5T33MM
cells (GFPneg cells) into Kal-Col-GFP transgenic mice that
express the emerald GFP protein (emdGFP) under the control of
the type-I collagen 2.3-kb promoter, which is expressed by
osteoblastic lineage cells38. Individual DiDhi 5T33MM cells were
localized directly adjacent to bone surfaces occupied by
emdGFPþ cells (Fig. 5d). These data suggested that the
endosteal niche actively suppressed myeloma cell growth. We
therefore cultured DiDhi cells in osteoblast-conditioned media or
co-cultured them with MC3T3 murine osteoblast-like cells and
demonstrated increased numbers of GFPþDiDhi cells in both
systems as compared with control. These data suggest that factors
made by osteoblasts suppressed proliferation, maintaining
GFPþDiDhi cells in a dormant state (Fig. 5e,f). In contrast,
media conditioned by RAW264.7 macrophages, a surrogate for
osteoclasts, promoted the proliferation and growth of
GFPþDiDhi cells, whereas myeloma cell-conditioned media
had no effect (Fig. 5e).
We next asked whether release of dormant myeloma cells from
the endosteal niche would reverse this suppression, and whether
re-engagement with the endosteal niche by active myeloma cells
would return them to a dormant state. In the ﬁrst instance, we
FACS-sorted GFPþDiDhi cells from disease-bearing mice on day
17 and cultured them in vitro. By day 4, cultured individual
GFPþDiDhi cells had divided to form small clusters of 2–6
GFPþ cells with a diminished DiD label (Fig. 5g). By day 14, the
cells had completely lost the DiD label through proliferation, and
the cell number and DNA content had correspondingly increased
(Fig. 5g,h). This was recapitulated in vivo by FACS-sorting
GFPþDiDhi cells, 21 days after cell inoculation, and relabelling
with DiD before secondary inoculation into naive mice (Fig. 5i).
Upon transfer, these previously dormant cells proliferated and
formed tumours. Reciprocally, FACS-sorted active GFPþDiDneg
cells, labelled with an alternative membrane dye CMDiI, were also
able to recolonize bone and form tumour (Fig. 5j). Importantly, a
small fraction of the CMDil-labelled cells localized adjacent to the
endosteal bone surface, retained their dye label and hence did not
divide (Fig. 5k). Thus, even though the cells had previously been
actively dividing, re-engagement with the endosteal niche was
able to suppress the growth of a subpopulation of these cells and
switch on dormancy in vivo. Remarkably, dormant cells were
detected adjacent to bone surfaces in mice inoculated with either
GFPþDiDhi- or GFPþDiDneg-relabelled cells at similar frequen-
cies, indicating that dormancy was not an intrinsic property of
the cell (Fig. 5k). Collectively, these data suggest that suppression
of myeloma cell growth by the endosteal niche is a transient
reversible state that can be switched ‘on’ or ‘off’.
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Figure 3 | Labelling and tracking dormant myeloma cells in vivo. (a) FACS analysis of bone marrow (BM) cells after inoculation of GFPþDiD-labelled
5TGM1-eGFP cells. Numbers indicate percentages in the gates. (b) Percentage of total BM of GFPþDiDhi dormant cells and GFPþDiDneg cells by FACS
analysis from a (individual data points and mean±s.e.m., one-way ANOVA). (c) Two-photon images of the metaphyseal region of explanted tibias
harvested at days 3 and 21. White, bone; red, GFPþDiDþ cells (white arrows); green, GFPþDiDneg cells. Scale bars, 200mm. (d) Enumeration of
GFPþDiDþ cells (meanþ s.e.m.). Data represent 4–5 individual mice. (e) FACS plots of BM samples from naive (no cells), mice injected with GFP cells not
labelled with DiD (GFPþDiDneg) or injected with DiD-labelled GFPþ cells (GFPþDiDþ), % of BM cells presented. (f) FACS plot demonstrating the three
populations of cells examined in g–i. (g) Histograms showing the frequency of cells that are CD11bþ , Gr-1þ , CD138þ or B220þ for each cell population
from f. (h) FACS plots showing distribution of CD11b and Gr-1-expressing cells in each GFP/DiD population from f. (i) Table showing the % of cells
(meanþ s.e.m.) that are CD11bþ , Gr-1þ , CD138þ or B220þ for each cell population from f. (j) Transcript proﬁle of GFPþDiDhi and GFPþDiDneg cells
showing the expression level of plasma cell, naive B-cell and myeloid lineage genes.
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Limited numbers of dormant myeloma cells get activated. To
study dormant myeloma cells and their transition to actively
proliferating cells, we performed longitudinal two-photon ima-
ging of the tibia from the same mice at 7, 14 and 20–21 days post
cell inoculation (Fig. 6a,b). At day 14, small GFPþ colonies were
visualized adjacent to bone surfaces (Fig. 6a), which on re-ima-
ging at day 20 had increased in size and were associated with
what appeared to be osteolytic lesions in the cortical bone
(Fig. 6a, right panels; Supplementary Movie 4). At day 7, indi-
vidual dormant GFPþDiDhi cells were localized to endocortical
bone surfaces and limited numbers of small individual colonies,
containing o10 GFPþDiDneg cells per colony, were identiﬁed
(Fig. 6b). Re-imaging at days 14 and 21 demonstrated the per-
sistence of dormant GFPþDiDhi cells (arrows) and the devel-
opment of activated GFPþDiDneg colonies (Fig. 6b).
Importantly, dormant GFPþDiDhi cells, transitioning to actively
growing GFPþDiDneg cells, were also visualized (Fig. 6b, circles).
Immunohistochemistry revealed discrete CD138þ tumour colo-
nies (Fig. 6c) and single, CD138þ cells that had not divided
adjacent to bone surfaces, consistent with the intravital imaging
(Fig. 6c, bottom right panel). Similar results were obtained with
the 5T2MM murine model of myeloma (Fig. 6d). The proportion
of medullary cavity occupied by CD138þ cells increased until it
was completely replaced by tumour (Fig. 6e, left panel). Notably,
the tumour colony count reached a maximum at day 14 post
inoculation before decreasing in number, reﬂecting the coales-
cence of colonies (Fig. 6e, right panel). In contrast, the number of
single CD138þ cells always exceeded the maximum number of
colonies (Fig. 6e, middle panel). Taken together, these data sug-
gest that only a small proportion of GFPþDiDhi cells are acti-
vated to form proliferating GFPþDiDneg colonies, while the
remainder were maintained in a dormant state.
Dormant myeloma cells are resistant to melphalan. Since
conventional anticancer drugs target actively dividing cells, we
examined the response of GFPþDiDhi and GFPþDiDneg cells to
melphalan, an alkylating agent commonly used to treat myeloma.
Indeed, microarray analysis and GSEA demonstrated that gene
sets involved in the response and sensitivity to melphalan were
negatively enriched in dormant GFPþDiDhi cells, suggesting that
these cells may be resistant to melphalan due to their lack of
proliferation (Fig. 7a). To test this, we treated disease-bearing
mice with melphalan and quantiﬁed the response by enumeration
of dormant GFPþDiDhi cells and activated GFPþDiDneg cells by
FACS analysis and two-photon microscopy of explanted tibia
(Fig. 7b–d). While all mice responded to melphalan with sig-
niﬁcant decreases in tumour burden, the response was variable
with some mice achieving 499% reduction, and others only able
to achieve 90–99% reduction (Fig. 7b). Nevertheless, despite the
decrease in GFPþ myeloma cells, dormant GFPþDiDhi cells
were remarkably stable and could be detected in all mice while on
treatment, with the proportion of GFPþDiDhi cells increasing
relative to total GFPþ cells (Fig. 7b). Consistent with this, two-
c d e
DiDhi
DiDNeg
f
Tuba4a
Rpa3
Hist1h2bh
Hist1h4a
Ndc80
Pmf1
Fgfr1op
Psmd10
Hist1h2bg
Reactome cell cycle
0.0
–0.2
–0.4
–0.6
P < 0.001
FDR < 0.001
Ola1
Ect2
Rps6ka2
Dtl
Bckdhb
Sf3b5
Banf1
Rpa3
Trip13
Proliferating vs quiescent HSC
0.0
–0.2
–0.4
–0.6
P < 0.001
FDR < 0.001En
ric
hm
en
t s
co
re
Ndc80
Casp8ap2
Terf2
Pmf1
Hinfp
Vps4a
Esco2
Klhdc3
Katna1
Cenph
Anapc10
Gsg2
2610039c10Rik
Kif20b
Suv39h2
Trip13
Wee1
Rps6ka2
Chek2
Fam83d
Cell cycle  GO:0007049
g
a bDiDneg
DiDneg
DiDhi
DiDhi
DiDnegDiDhi
DiDnegDiDhi DiDnegDiDhi DiDnegDiDhi
DiDnegDiDhigh
DAPI
Ki
67
G2/M
8.9
S
6.9
G1
29.6
G0
45.4
G2/M
17.8
S
15.7
G1
58.0
G0
7.9
G0 G1 S G2/M
0
20
40
60
80
0
20
40
60
80
0 0
10
20
30P<0.001 P<0.001 P<0.05
10
20
30 P<0.001
%
DiDneg
GFP
D
iD
105
104
103
103
103
102
–102
104
104 105
0
0 50K 50K100K 100K150K 150K200K 200K250K 250K0
0
Differentially regulated transcripts
N=31,235 P<0.0001 q<0.05 FC>2 FC>4
hi vs neg 514 6,262 991 97
Figure 4 | Conﬁrmation of GFPþDiDhi cell population as dormant myeloma cells. (a) FACS plot showing gating of GFPþ DiDhi and GFPþ DiDneg cells in
G0, G1, S and G2/M cell cycle phases as determined by Ki67 expression and DAPI staining on day 21. FACS plot shown is pooled data from ﬁve mice.
(b) Distribution of DiDhi and DiDneg cells in G0, G1, S and G2/M phase of the cell cycle from gating shown in a. Data represent 4–5 individual mice
(mean±s.e.m., paired t-test). (c) Gates used for FACS sorting of GFPþDiDhi and GFPþDiDneg cells. (d) Heatmap showing differentially expressed genes.
(e) Table of differentially transcribed genes between the three cell populations. (f) Gene expression analysis showing genes involved in cell cycle and
replication, transcriptional and translational activity, which were expressed at lower levels in dormant cells when compared with GFPþDiDneg cells isolated
from the same mice. (g) Selected regulatory gene sets determined by GSEA, including negative enrichment for gene sets related to cell cycle progression
and regulation of HSC quiescence in DiDhi vs DiDneg cells. Dot plots represent concatenated myeloma populations from six tumour-bearing mice.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9983
6 NATURE COMMUNICATIONS | 6:8983 | DOI: 10.1038/ncomms9983 | www.nature.com/naturecommunications
100806040200 100 200 300 400 500
G
FP
+
D
iD
+
 
ce
lls
 (%
) Day 1
Day 3
Day 7
Day 10
Day 14
Day 17
Day 21
2
4
6
8
10
12
14
DiD+/
Kal-Col-GFP
GFP+DiD+
Fr
e
qu
en
cy
 (n
u
m
be
r o
f c
el
ls)
GFP+DiDneg
20
15
10
5
0
25
30
35
12 µm 55 µm
P<0.0001
 Distance from 
bone surface (µm)
 Distance from 
bone surface (µm)
40
80
120
0
pOsB 
Control CM
RAW 264.7 
Control CM
40
80
120
0
Ce
lls
 (×
10
3 )
P<0.0001
P=0.004
7 Days 14 Days
0.10
1
10
100
D
iD
hi
/5
TG
M
1-
G
FP
+
 
ce
lls
 (%
)
P<0.0001
P=0.007
ctrl
MC3T3
5TGM1 
40
80
120
0
Control CM
NS
Relabelling of 
cells with
 
i.v. injection of 
relabelled cells
Isolation of 
cells
Cells from 
1st isolation
 GFP+DiDneg 
DiD labelling of 
5TGM1-eGFP cells
GFP+
DiDneg
GFP+
DiD+
GFP+
CMDiIneg
GFP+
CMDiI+GFP+CMDiI+
GFP+DiD+GFP+DiD+
Day 4 
D
iD
G
FP
O
ve
rla
y
TL
Day 0 Day 14
Days post sorting
0 14 20
Ce
lls
 (×
10
3 )
102
104
106 P=0.0435
0 4 7 10 14
0
20
40
60
80
100
120
D
N
A 
(µg
)
P<0.0001
Dormant cells – 2nd isolation
GFP+CMDiI+ GFP+DiD+
*
D
or
m
an
t c
el
ls
 m
m
–
2
GFP+
CMDiI+
GFP+
DiD+
800
200
400
600
0
NS
SS
C
Myeloma burden – 2nd isolation
 GFP
GFP+CMDiIneg GFP+DiDneg
G
FP
+
 
ce
lls
 (%
)
0
1
2
2.5
1.5
0.5
GFP+
CMDiIneg
GFP+
DiDneg
NS
100
1.0k
800
600
400
200
0
1.0k
800
600
400
200
0
100 101 102 103 104 10
0 101 102 103 104
a b c
d e f
g h i
j k
Figure 5 | Dormancy can be switched on and off by the bone environment. (a) Measurement of distance of GFPþDiDþ cells to the nearest bone
surface. (b) Comparison of the location of GFPþDiDþ and GFPþDiDneg cells. Arrows indicate median distance from bone surface. (c) Three-
dimensional two-photon image of green GFPþDiDneg cells (white arrow) and yellow GFPþDiDþ cells (red arrows) localized to the bone surface, blue;
scale bar, 100mm. (d) Two-photon image of a DiD-labelled 5T33MM cell (arrow) localizing to the bone surface (SHG, white) lined with osteoblasts
(col2.3 GFPþ, green). (e) Effect of conditioned media (CM) from primary osteoblasts (pOsB, left panel), macrophage cell line (RAW264.7, middle panel)
and myeloma cells (5TGM1, right panel) on cancer cell dormancy, unpaired t-test. (f) Effect of co-culture with osteoblast cell line MC3T3 on cancer cell
dormancy. (g) Fluorescent and bright-ﬁeld microscopy from in vitro cultures of FACS-sorted GFPþDiDhi long-term dormant cells; scale bar, 25mm.
(h) Cell count and DNA content of in vitro cultures from g, one-way ANOVA. (i) Schematic for isolation (day 21 post inoculation) and reinoculation of
dormant GFPþDiDþ and activated GFPþDiDneg cells. (j) FACS analysis of bone from mice after second passage for myeloma cell burden. Data show
percentage of GFPþ per bone marrow cells (mean±s.e.m., unpaired t-test). (k) Localization of dormant GFPþCMDiIþ (white arrows, left panel) and
dormant GFPþDiDþ (white arrows, middle panel) cells adjacent to bone surfaces from two-photon microscopy of ex vivo tibia (bone, white) and
enumeration of GFPþCMDiIþ and GFPþDiDþ cells per mm2 bone. Scale bars, 200mm. Data in e,f,h,j and k show mean±s.e.m. Data represent at least
two experiments. NS, not signiﬁcant.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9983 ARTICLE
NATURE COMMUNICATIONS | 6:8983 | DOI: 10.1038/ncomms9983 |www.nature.com/naturecommunications 7
photon microscopy demonstrated a reduction in GFPþDiDneg
cells and a persistence of GFPþDiDhi cells apposed to endosteal
surfaces (Fig. 7c,d). These data suggest that dormant GFPþDiDhi
cells are resistant to melphalan and may contribute to disease
relapse upon drug withdrawal. In contrast, treatment of disease-
bearing mice with bortezomib, which targets both dividing and
non-dividing cells, reduced myeloma burden and also the pro-
portion of GFPþDiDhi dormant cells, suggesting that dormant
cells may respond differently to different agents (Supplementary
Fig. 2).
To directly address the contribution of GFPþDiDhi cells to
disease relapse, we treated disease-bearing mice with melphalan
for 14 days, identiﬁed individual dormant GFPþDiDhi cells and
actively growing GFPþDiDneg colonies by intravital imaging and
then re-imaged the same mice either 7 or 14 days after treatment
withdrawal to track their fate. Following treatment cessation,
FACS analysis demonstrated a signiﬁcant increase in the number
of GFPþDiDneg cells, conﬁrming escape from therapeutic control
and mimicking disease relapse (Fig. 7e). However, unlike in the
treatment setting, dormant GFPþDiDhi cell numbers decreased
following treatment withdrawal, consistent with their reactivation
and their role in repopulating the tumour (Fig. 7e). In support of
this, longitudinal intravital two-photon microscopy demonstrated
a reduction in individual GFPþDiDhi cells as the tumour
repopulated the marrow following cessation of treatment at
day 28 (Fig. 7f, circles).
Bone resorption activates dormant myeloma cells. To directly
test the impact of manipulating the bone microenvironment on
disease activity, we treated disease-bearing mice with a soluble
form of the ligand for the receptor activator of NFkB (sRANKL),
which is expressed by osteoblasts and osteocytes and is critical for
osteoclast formation and bone resorption39. Daily treatment with
sRANKL for 3 days in naive BKAL mice resulted in a signiﬁcant
reduction in trabecular bone volume and bone surface (Fig. 8a,b),
along with a signiﬁcant decrease in trabecular number and an
increase in trabecular separation (data not shown). These
structural changes in bone were associated with an increase in
osteoclasts within trabecular bone regions and on endocortical
bone surfaces (Fig. 8c,d) and an increase in serum tartrate-
resistant acid phosphatase, a marker of osteoclast activity (Fig. 8d,
bottom panel). Importantly, FACS analysis demonstrated that
manipulation of the bone microenvironment resulted in a
signiﬁcant decrease in the number of dormant GFPþDiDhi
cells in the bone marrow, as anticipated (Fig. 8e). Interestingly,
although there was also a modest reduction in myeloma burden,
there were fewer GFPþDiDhi cells as a proportion of the GFPþ
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tumour burden (Fig. 8e). Importantly, sRANKL treatment had no
effect on myeloma cells in the spleen (Fig. 8f), conﬁrming that the
effect on GFPþDiDhi cells was a myeloma cell-extrinsic effect
mediated by osteoclasts in the bone, with osteoclast activation
associated with the release of GFPþDiDhi cells from the
endosteal niche. Quantitative assessment of GFPþDiDþ and
GFPþDiDneg cells by two-photon microscopy conﬁrmed the
decrease in numbers of GFPþDiDþ cells relative to both
bone marrow volume and GFPþDiDneg tumour (Fig. 8g,h).
Interestingly, intravital imaging did not demonstrate a decrease in
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GFPþDiDneg tumour burden, which may reﬂect the smaller
sample volume or a differential distribution of tumour, compared
with analysis by FACS. Thus, sRANKL induces osteoclastic
bone resorption and can release dormant myeloma cells from
osteoblastic or bone-lining-cell suppression, making them
available to contribute to disease progression and/or relapse. To
establish whether bone resorption is associated with myeloma
burden, we examined serum levels of C-terminal telopeptide
(CTX), a biochemical marker of bone resorption, and
b2-microglobulin (b2m) as a measure of tumour burden in 118
patients with newly diagnosed myeloma. CTX was signiﬁcantly
correlated with b2m (R2¼ 0.3588, Po0.0001, Pearson’s
correlation), suggesting that increased bone resorption is related
to tumour burden in patients (Fig. 8i). Taken together, these data
suggest that dormant cells held in the endosteal niche can be
reactivated by osteoclasts remodelling the endosteal niche
(Fig. 8j).
Discussion
Cancer cell dormancy is increasingly recognized as an important
clinical problem. Despite improved outcomes from new, targeted
therapies, patients continue to suffer from relapse and metastases,
which are major causes of morbidity and mortality. Thus, there is
an increasing need to understand cancer cell dormancy to prevent
drug resistance and disease relapse. This is particularly true in
multiple myeloma where patients now achieve complete
responses to state-of-the-art combination therapy, yet still
harbour drug-resistant dormant myeloma cells as MRD and go
on to progress at a later time point. Consequently, understanding
the extrinsic control of dormant myeloma cells by the bone
microenvironment has the potential to uncover novel therapeutic
approaches. These may be used in combination with current
treatments to either completely eradicate myeloma cells, or to
maintain MRD in a dormant state and achieve long-term
remission. Accordingly, we developed a unique, non-destructive,
method to track the fate of individual myeloma cells, long-
itudinally, as they colonize the endosteal niche and form tumour
colonies over weeks or months, in live mice by intravital two-
photon microscopy. By imaging through a natural optical
window in the tibia, we have overcome the long-held misconcep-
tion that non-destructive intravital microscopy of bone can only
be performed in the calvaria. Importantly, the tibia has different
developmental origins from the calvaria and may also contain
distinct anatomical and functional compartments that constitute
the specialized microenvironments required for myeloma cell
colonization, retention of dormancy and growth. Using this novel
approach, we demonstrated that myeloma cells entered the bone
marrow, left the vasculature and migrated directly towards
endosteal surfaces where they arrested in sites containing type-I
collagen-expressing osteoblasts or bone-lining cells. This is
consistent with the immunohistochemical studies reporting the
presence of leukaemic cells and primary myeloma cells adjacent
to bone surfaces11,40.
Our intravital studies of myeloma cell dormancy were
facilitated by the use of a lipophilic membrane dye, DiD, to
identify dormant GFP-expressing myeloma cells that had not
undergone cell division. This was supported by the detection of
stable numbers of these cells throughout the duration of the
experimental time course following initial equilibration, indicat-
ing that they are long-lived dormant cells. In addition, analysis of
Ki67 expression and DAPI staining showed that the majority of
GFPþDiDhi cells were in the resting G0 phase when compared
with the GFPþDiDneg population. Furthermore, transcriptional
analysis demonstrated that the GFPþDiDhi population main-
tained this long-lived persistent dormant phenotype by down-
regulating genes that control the cell cycle. Interestingly, a limited
number of the GFPþDiDhi cells were also Ki67 positive,
suggesting that, in certain niches, dormant cells may have
recently been activated to divide. This challenges the notion that
dormancy is a synchronized period of inactivity and supports the
idea that dormancy may instead result from the dynamic
interplay between myeloma cells in the multiple heterogeneous
niches and may exist in different states of activation.
To establish whether dormancy was a ﬁxed or reversible state,
we removed dormant GFPþDiDhi cells from their bone niche,
relabelled them with DiD and reinoculated them into naive mice.
We showed that some of the GFPþDiDhi cells remained dormant
while others were released from dormancy in their new
microenvironment and became activated to form GFPþDiDneg
colonies. Remarkably, in the reciprocal experiment, when we
removed proliferating GFPþDiDneg cells and labelled them with
CMDiL before reinoculation, these cells not only formed colonies
but could also be induced to enter a dormant state in their naive
host bone environment. These observations infer that cancer cell
dormancy is a reversible state that can be switched ‘on’ or ‘off’ by
microenvironmental signals. Interestingly, we also showed that of
the many dormant tumour cells that locate to the endosteal niche,
only limited numbers become reactivated to form overt myeloma
colonies. This is reminiscent of the ‘clonal tides’ and altering
clonal dominance that is observed in patients exposed to different
drug regimens6,8–10. In addition, the plasticity of the 5TGM1 cells
under these experimental conditions and the fact that 89%
of GFPþDiDhi cells are CD138þ suggests that dormant
myeloma cells are distinct from cancer stem cells, which are
thought to be poorly differentiated cancer cell precursors41,
and the myeloma stem cell, which have been reported to be
CD138neg (refs 42,43).
Crucially, the proportion of dormant GFPþDiDhi and
proliferating GFPþDiDneg myeloma cells that form colonies
Figure 8 | RANKL-driven alterations in the endosteal niche activate dormant tumour cells. (a) Three-dimensional reconstructions of MicroCT scans of
representative tibia from vehicle- and RANKL-treated naive mice after 3 days of treatment. (b) Trabecular bone volume of total volume (BV/TV) and
trabecular bone surface (BS) in metaphyseal bone in vehicle- and RANKL-treated mice. (c) Representative sections of TRAP-stained tibia from trabecular
and endocortical regions of vehicle- and RANKL-treated naive mice; scale bar, 100mm. (d) Histograms of osteoclast surface per mm bone surface for
trabecular (top) and endocortical (middle) bone and serum TRAP levels (bottom). Data are from one experiment with 9–10 mice per group. (e) FACS
analysis of GFPþDiDneg cells (left, % of bone marrow cells), GFPþDiDhi (middle % of bone marrow cells) and percent GFPþDiDhi (right % of GFPþ) from
bone marrow samples. (f) FACS analysis of GFPþ cells (left, % of spleen cells), GFPþDiDhi (middle, % of spleen cells) and GFPþDiDhi (right, % of GFPþ)
from spleen samples. (g) Analysis of two-photon mosaic tiles of total number of GFPþ cells (left), number of GFPþDiDhi cells (middle) and GFPþDiDhi
(right % of GFPþ) in the analysed endocortical region. Data show mean±s.e.m. and represent 6–10 mice per group, unpaired t-test. (h) Two-photon
generated 3D images of multiple GFPþDiDþ dormant cells (white arrows) in the vehicle-treated mice compared with few or none in the RANKL treated;
scale bars, 60 mm. (i) Correlation between serum CTX and serum b2m levels in myeloma patients, Pearson’s correlation. (j) Schematic depicting myeloma
cell dormancy on quiescent bone surfaces and myeloma cell reactivation on actively resorbing bone surface. Data are from one experiment with six mice
per group.
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or became dormant after secondary transplantation were
comparable. This indicated that stochastic engagement with the
relevant bone niche was more important than an intrinsic
developmental programme in determining the fate of the
transplanted myeloma cells. Consistent with this, osteoblast-
conditioned media and co-culture with MC3T3 osteoblast-like
cells maintained dormancy and suppressed proliferation, whereas
osteoclast-like cell-conditioned media stimulated myeloma cell
growth. This is consistent with studies in vitro, which show that
growth of patient-derived multiple myeloma cells is suppressed
when cultured with patient-derived osteoblasts and inhibition of
myeloma growth when patient-derived MSCs are delivered
systemically or directly into bones of SCID-hu MM-bearing
mice44,45. While the mechanisms responsible for suppression of
multiple myeloma cell growth and holding MM cells in a
dormant state are poorly deﬁned, they may include release of
bone morphogenic proteins46 or secretion of Wnt proteins and
Wnt antagonists47,48. Furthermore, our gene expression analysis
has identiﬁed a number of cellular adhesion molecules and
membrane receptors, including Vcam1 and Axl, that could also
play a role in interactions between dormant myeloma cells and
cells in the endosteal niche. Importantly, expression of these
molecules may be used as biomarkers to help identify dormant
myeloma cells in bone and may also provide new therapeutic
targets to aid in the erradication of these cells. Taken together,
these data suggest that the extrinsic bone microenvironment, and
likely an endosteal niche, plays a critical role in controlling
myeloma cell dormancy.
Dormant GFPþDiDhi cells were more resistant than prolifer-
ating GFPþDiDneg cells to melphalan treatment, but not to the
proteasome inhibitor bortezomib. This may argue that dormant
cells are intrinsically resistant to chemotherapeutic agents that
target dividing cells by virtue of their dormant state. Moreover,
even in mice with 499% reduction in tumour burden, GFPþ
DiDhi cells were still detectable and contributed to the re-
establishment of myeloma growth following melphalan treatment
withdrawal. This ‘awakening’ of dormant cells during recovery
may be a result of alterations in the local environment. Therefore,
we tested the hypothesis that direct manipulation of the bone
microenvironment itself would impact on dormancy and provide
a mechanism for reactivating dormant cells. Short-term treatment
with sRANKL increased osteoclast numbers, resorption activity
and decreased the bone surface containing endosteal niches. This
osteoclastic activity released GFPþDiDhi cells from dormancy
and resulted in a speciﬁc reduction of GFPþDiDhi cells in the
bone, but not in the spleen. Consistent with this, serum CTX
levels were found to correlate with serum b2m, a marker of
tumour burden, in a large cohort of patients with newly
diagnosed multiple myeloma. These data suggest that bone
resorption, simply by remodelling the endosteal niche as part of
normal physiological function, may inadvertently activate dor-
mant tumour cells, arguing that activation of dormant cells is an
environmentally controlled stochastic event. Interestingly, despite
the increased osteoclast activity following RANKL treatment, not
all of the bone surface undergoes resorption and as a result
dormant cells are still present, suggesting mobilization events are
a localized phenomena. The reason why mobilization of dormant
cells was associated with a reduction in myeloma burden is
unclear. This could reﬂect a difference in the rate of growth of
mobilized cells following treatment or alternatively that, dormant
cells that were mobilized by sRANKL died without undergoing
cell division; however, the latter is not consistent with our studies,
showing these cells have the capacity to grow in vitro and in vivo
(Fig. 5). Nevertheless, these data suggest that stimulation of bone
resorption may result in synchronized activation of dormant cells,
thereby rendering them more susceptible to targeted therapies. Or
that inhibition of bone resorption by anti-resorptive agents, such
as bisphosphonates, may enforce cellular dormancy and prevent
myeloma cell activation and relapse.
These data therefore have signiﬁcant clinical implications. We
already know inhibitors of bone resorption, including
bisphosphonates and strategies to block RANKL, reduce myeloma
burden in experimental models49–51. Furthermore, bisphospho-
nate treatment is associated with improvements in survival that
may be independent of the development of skeletal-related
events52; however, the mechanisms responsible remain unclear.
These data may provide at least one explanation for these
observations, that is, that bisphosphonate treatment may prevent
reactivation of dormant myeloma cells. It could also argue that
consideration needs to be given to very early anti-resorptive
treatment to prevent activation of dormant tumour cells to sustain
long-term remission. This is certainly supported by studies in
patients with monoclonal gammopathy of undetermined
signiﬁcance, which show that patients with increased bone
resorption are more likely to develop overt myeloma53.
The experimental data presented here provide the basis for
developing novel approaches to prevent disease progression in
myeloma. This could include repurposing bone-active drugs as
frontline therapies, to be used in combination with targeted
therapies, to prevent the reactivation of dormant myeloma cells
and sustain long-term remission. Alternatively, the promotion of
bone resorption to release tumour cells from dormancy may
facilitate their targeting by the existing armamentarium of drugs
to eliminate MRD and achieve long-term remission or even cure.
Finally, further studies of the molecular mechanisms that regulate
dormancy within the endosteal niche may reveal druggable targets
that control myeloma reactivation. Thus, this new knowledge of
the extrinsic control of cancer cell dormancy has implications for
understanding cancer pathogenesis and the potential to unlock
opportunities for developing innovative treatment strategies.
Methods
Mice and in vivo mouse models. Six-to-eight-week-old C57BL/KaLwRijHsd
(BKAL) male mice (Harlan, Netherlands) were injected intravenously with 2 106
syngeneic 5TGM1-eGFP (a gift from Dr Oyajobi, University of Texas Health
Sciences Center San Antonio, Texas, USA) or 5T33MM murine myeloma cells in
200 ml PBS54,55. Cells were negative for mycoplasma. On speciﬁed days post
injection, mice were killed for FACS analysis and two-photon imaging of explanted
bones. In separate studies, 6–8-week-old male BKAL mice were injected with
5T2MM murine myeloma cells and killed 7 weeks later to examine tumour colony
formation. BKAL mice were also crossed with mice expressing emerald GFP under
the type-I collagen promoter (pOBCol2.3GFPemd)38 to produce C57BL/
KaLwRijHsd.Cg-Tg (Col1a1-GFP) denoted as Kal-Col-GFP mice to mark
osteoblastic cells in vivo. For drug studies, BKAL mice were injected with DiD-
labelled 5TGM1-eGFP cells. After 2 weeks, mice were injected, intraperitoneally,
three times a week for 2 weeks with melphalan (Sigma-Aldrich, 5mg kg 1 in
17.5% ethanol) or vehicle56; or twice a week, subcutaneously, with bortezomib
(Sigma-Aldrich, 0.7mg kg 1 in 0.005% dimethylsulphoxide). Mice were killed 4
weeks later and 1 or 2 weeks after cessation of melphalan treatment. Tibia, femurs
and spleens were isolated for FACS and two-photon imaging. Drug studies were
performed in two separate experiments. Recombinant soluble RANKL-GST fusion
protein (RANKL, Oriental Yeast Company Ltd, Tokyo, Japan) or saline was
administered at a dose of 0.5mg kg 1 intraperitoneally daily for 3 days in naive
mice before harvest on day 4. RANKL was administered on days 4–6 post cell
injection and experiments ceased 18 days later. Experiments were approved by
the Garvan Institute/St Vincent’s Hospital (#12_20), University of Shefﬁeld (PPL
40/3,462) and Vrije Universiteit Brussel (#13-281-5) Animal Ethics Committees.
Cancer cell lines and intravital labelling of dormant cells. 5TGM1-eGFP and
5T33MM myeloma cells were cultured in RPMI-1640 supplemented with 10% fetal
calf serum (FCS) and 1% penicillin–streptomycin, and incubated in 5% CO2 at 37 C
(refs 54,55). 5T2MM cells were maintained by serial passage in BKAL mice54.
Cells were labelled with DiD, or 3H-Indolium, 5-[[[4-(chloromethyl)benzoyl]amino]
methyl]-2-[3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-1-
propenyl]-3,3-dimethyl-1-octadecyl-, chloride (CMDiI) (Molecular Probes).
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In vitro conditioned media and co-culture experiments. Primary osteoblasts
were isolated from calvaria of 2–4-day-old C57BL/6 mice and differentiated in
MEMa supplemented with ascorbic acid, b-glycerol phosphate, ribonucleosides
and 10% FCS for 4 weeks57,58. DiD-labelled 5TGM1-eGFP cells were cultured
either in media, or in media conditioned with 5TGM1, RAW264 cells or primary
osteoblasts. DiD-labelled 5TGM1-eGFP cells were co-cultured with MC3T3
murine osteoblast-like cells plated in RPMI, supplemented with 10% FCS, 1%
penicillin/streptomycin and 1% Glutamax.
Two-photon microscopy of explanted tibias and femurs. At the University of
Shefﬁeld, the tibia or femur were embedded in OCT solution (Tissue-Tek) and
snap-frozen in liquid nitrogen before cryosectioning. Images were acquired with an
inverted Zeiss 510 META (Carl Zeiss). Two-photon excitation at 820 nm was
achieved with a Chameleon XR Ti:Sa laser (Coherent) and ﬂuorescence detected
using the following: BP435-485 to detect blue (second-harmonic generation), BP
500–550 to detect green (GFP), BP 565–615 IR to detect orange/red (CMDiI) and
BP 650–710 nm to detect far-red (DiD). In some images (Figs 3 and 4;
Supplementary Fig. 2) this was pseudocoloured white. Three-dimensional (3D)
mosaic tiles were performed at 128 128 pixel resolution and individual
450 450 150 mm volumes imaged at 256 256 pixel resolution in 2-mm z-steps.
Three-dimensional volumes were reconstructed and analysed using Volocity
software (Improvision, Perkin Elmer). At the Garvan Institute of Medical Research,
imaging was performed on intact tibias or cryosectioned femurs using an upright
Zeiss 7MP microscope (Carl Zeiss). We used LBF 760 and BSMP2 760 ﬁlters to
enable detection of the far-red emission of BSA-Alexa Fluor680 and DiD. Four
external non-descanned detectors were used to detect blue (second-harmonic
generation, SP 485), green (BP 500–550), red (BP 565–610) and far-red (BP
640–710). Infrared excitation at 920 nm was provided by a Chameleon Vision II
Ti:Sa laser (Coherent Scientiﬁc). Each 512 512-pixel xy-plane was acquired
at 2–3-mm z-step intervals. Time-lapse images were acquired at 30-s intervals.
Images were acquired using ZEN 2009 software (Zeiss) and raw image ﬁles
processed using Imaris (Bitplane). Red dormant cells and green activated cancer
cells were counted using the spot detection function in Imaris.
Real-time intravital two-photon microscopy of the tibia. Mice were anaes-
thetized as described59. Anaesthetized mice were kept warm using a customized
heated SmartStage (Biotherm). An incision was made over the medial surface of the
tibia and soft tissue resected. Mice were intravenously injected with a single dose of
Alexa Fluor680/bovine serum albumin (2.5–10.0mg kg 1, Invitrogen) to label
blood vessels. 5TGM1-eGFP cells were injected four frames (2min) after
commencement of imaging. A Gaussian ﬁlter was applied and the display adjusted
to reduce background noise and improve contrast in Imaris. Videos were compiled
and annotated using Adobe AfterEffects (Adobe). Myeloma cells were counted as
circulating cells if they entered and left the imaging volume within two consecutive
frames. Colonizing cells entered, crawled and arrested within the imaging volume
and could be found in the same location again at least 5min later.
Longitudinal intravital two-photon microscopy of the tibia. For longitudinal
imaging, 2 106 DiD-labelled 5TGM1-eGFP cells were injected 7 days before the
initial imaging session. During imaging, a 3D mosaic tile image was captured to
include the growth plate and other landmarks as ﬁducial markers to enable
repeated imaging of the same volume. Mice were recovered after imaging, the skin
sutured and buprenorphine hydrochloride 0.5mg kg 1 subcutaneously adminis-
tered. Mice were re-imaged on days 14 and 21 in the same region based on the
position of the ﬁducial markers.
Micro-computed tomography of the tibia. Bones were scanned using a mCT
scanner (Model 1172; Skyscan) at 50 kV, 200mA with a 0.5-mm aluminium ﬁlter using
a pixel size of 4.3mm. Images were captured every 0.4˚ through 180˚, reconstructed and
analysed using NRecon and CTAn software (Skyscan). Three-dimensional models were
created using the Drishti-2 tool (https://code.google.com/p/drishti-2/).
Histology. Bones were ﬁxed in 4% paraformaldehyde, decalciﬁed in EDTA,
embedded in parafﬁn and 4-mm sections were cut. Antigen retrieval was performed
in trypsin (Biocare Medical) at 37C for 10min, and washed for 5min in PBS.
Nonspeciﬁc binding was blocked in 10% FCS and 10% normal goat serum (S-1000,
Vector Laboratories) for 1 h at room temperature (RT). Primary antibody (rat anti-
mouse anti-CD138, clone 281-2, BD Pharmingen) and isotype control (puriﬁed rat
IgG2a, k-isotype control, clone R35-95 BD Pharmingen) were incubated for 1 h at
RT at a dilution of 1:300 and washed in PBS. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide (Sigma) for 30min at RT. Primary antibody
was detected with a secondary biotinylated goat anti-rat IgG F(ab)2 fragment
(SC-3,826, Santa Cruz) incubated for 30min at RT and washed in PBS before
incubation with strepavidin-horseradish peroxidase (DakoCytomation) for 30min
at RT. Antigen/antibody complex was visualized with 3,3,diaminobenzadine
(SK-4105, Vector Laboratories) and counter-stained with haematoxylin.
CD138þ ve cells and colonies were counted and data expressed/bone section.
Identical data were obtained when data were expressed per unit area.
FACS analysis. Bones were ﬂushed with PBS/2% FCS, cut longitudinally and the
inner surface was scraped with a scalpel blade. Bones (including the epiphysis) were
minced and fragments ﬂushed with PBS/2% FCS. Cells were syringed ﬁve times
through a 23-G needle and ﬁltered through a 100-mm nylon cell strainer (Nunc).
Red cells were lysed with 0.15M NH4Cl. Cells were resuspended in PBS/2% FCS
and ﬁltered through a 70-mm strainer. For Ki67 staining, samples were incubated
with Fixable Viability Dye eFluor780 (eBioscience) and then Fc-blocked with anti-
mouse CD16/32 before ﬁxation with the Nuclear Factor Fixation and Permeabi-
lization Buffer Set (BioLegend). Cells were then incubated with PE anti-mouse Ki67
at a dilution of 1:100 (BioLegend) and DAPI to stain DNA. For CD11b, Gr-1,
CD138 and B220 staining, samples were incubated with Fixable Viability Dye
eFluor780, then Fc-blocked with anti-mouse CD16/32. Cells were then incubated
with PE anti-mouse B220, PERCP-Cy5.5 anti-mouse CD11b, Pe-Cy7 anti-mouse
CD138 (clone 281-2) and Brilliant Violet 450 anti-mouse Gr-1 (BioLegend) at a
dilution of 1:100. Samples were acquired on a FACSCanto II or LSR II SORP (BD
Biosciences). Analysis was performed with FlowJo software (Tree Star). For
microarray analysis, up to 50,000 cells were sorted using BD FACSAria II or BD
FACSAria III (BD Biosciences) directly into 0.5ml of TRIzol LS reagent (Life
Technologies Australia).
Transcript proﬁling. Total RNA was extracted using Trizol LS reagent and its
integrity measured using a Total RNA Pico Chip (Agilent Technologies) according
to manufacturer’s protocol. Complementary DNA was prepared and ampliﬁed
using the NuGEN Ovation Pico System V2, and hybridized with GeneChip Mouse
Gene 2.0 ST Arrays (Affymetrix). Normalization and probe set summarization was
performed using the robust multichip average implemented through the Affyme-
trix library within R60. Control probe sets were removed leaving 31,235 probe sets
on the array following batch-correction using SVA package in R61. Differential
gene expression was assessed for each probe set using an empirical Bayes,
moderated t-statistic implemented in Limma using the limmaGP tool in
GenePattern60. GSEA34 was performed with the GenePattern tool GSEA pre-
ranked using a ranked list of the Limma-moderated t-statistics against version 3.0
of the ‘C2_all’ curated gene sets from the MSigDB supplemented with gene lists
related to stem cell regulation, metastasis and melphalan treatment62,63. Functional
annotation of 867 signiﬁcant genes (fold change 42, Q-valueo0.05) was
performed using database for annotation, visualization and integrated discovery
(DAVID)64,65. All analyses were performed using GenePattern software66 and are
available at http://pwbc.garvan.unsw.edu.au/gp/. The microarray data have been
deposited in the GEO database under accession code GSE57695.
Patient serum analysis. Newly diagnosed myeloma patients, who had not
received chemotherapy, were included in this study. Ethical approval for this study
was obtained from the Royal Adelaide Hospital Human Research Ethics Com-
mittee and informed consent was obtained in accordance with the Declaration of
Helsinki. Staging was based on the ISS criteria. Of the 118 patients examined, 53
were female (median age at diagnosis, 67 years; range, 47–83 years) and 66 were
male (median age at diagnosis, 61 years; range, 49–74 years). Serum b2m, a marker
of tumour burden in renal-sufﬁcient patients, creatinine concentrations and
creatinine-based renal parameters (estimated glomerular ﬁltration rate and crea-
tinine clearance) were evaluated using an Olympus AU5400 Chemistry Analyzer.
Patients with renal insufﬁciency were excluded from further analysis. Serum levels
of C-terminal collagen crosslinks (CTX-1) were measured using a Roche modular
E170 analyzer (Roche Diagnostics, Castle Hill, Australia).
Statistical analysis. Data were analysed using Prism software (GraphPad). One-
way analysis of variance (ANOVA) and multiple comparisons were performed
using Tukey’s correction. Unpaired t-tests were performed when comparing two
populations. Non-parametric data were assessed using Kruskal–Wallis one-way
ANOVA. Two-way ANOVA were used for grouped analyses (co-culture) with
Sidak’s correction. Correlations between serum CTX-1 and b2m were assessed
using linear regression analysis. All data are expressed with error bars representing
s.e.m.
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